Lilly agrees to pay $29.4M to settle SEC bribery charges
According to a statement released by the SEC, Eli Lilly paid $6.5 million—and in some cases gave jewelry and spa treatments—to win government contracts in Brazil, China, Russia and Poland.
Health Care & Life Sciences
Articles
Indiana to receive nearly $793K in Amgen settlement
Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.
Lilly finds solace in new Alzheimer’s study
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
Health care pricing service comes to Indy
Chicago-based OkCopay Inc. posts prices offered by Indianapolis health care providers, many of which have agreed to give cash-paying patients a price roughly equivalent to those charged to insured customers. The site also includes pricing information from health care providers that do not give cash-paying patients an additional break.
State expects to extend Healthy Indiana Plan a year
The Centers for Medicare and Medicaid Services agreed to a waiver that would allow the state to continue the program unchanged for a year.
Actuarial firm plans expansion at Indy office
Milliman Inc. said it will add 26 jobs by 2017 and invest $2 million to install additional information technology equipment at its office in downtown’s Chase Tower.
IEDC seeks $30M fund to stoke life sciences firms
The Indiana Economic Development Corp. is looking to renew its commitment to life sciences by creating a $30 million venture fund. The amount dedicated to one sector would be equal to the state’s allocation for all high-tech startups over the past two years.
Apartments, shops planned for old Beech Grove hospital site
Dubbed Franciscan Place, the $20 million development will feature 150-plus senior-living apartments, shops and a restaurant in the old hospital. Work is expected to begin in February.
Lilly discontinues late-stage trial in rheumatoid arthritis
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Lilly plans another study for Alzheimer’s drug
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
WellPoint reaffirms 2012 earnings forecast
WellPoint Inc. is sticking with a 2012 earnings forecast that it had cut in July, and the nation's second-largest health insurer said it expects next year's earnings to be on par with this year's performance.
Report ranks Indiana among unhealthiest states
America's Health Rankings lists Indiana 41st in its annual review, which was released Tuesday. Obesity, sedentary habits, high smoking rates, low public health funding and air pollution contributed to Indiana’s low rank.
Q&A
Muhammad Yasin began heading up social media marketing at Indianapolis-based HCC Medical Insurance Services LLC in early 2011. The company, which sells travel insurance and short-term medical insurance online, credits his work with tripling overall revenue in 2011 to more than $60 million and growing even more this year. Yasin, along with a steady stream of interns, manages nearly 50 social media accounts on Facebook, Twitter, Pinterest and YouTube, and has about 400,000 total followers. Collectively, HCC’s social media team produces 2,000 pieces of “content” every month—even though it operates in a highly regulated industry.
Report: WellPoint dominates Indiana markets
WellPoint Inc. holds an overwhelming share of the commercial health insurance market in 13 of Indiana’s 14 largest metros, according to a controversial new study by the American Medical Association.
Analyst: Lilly solid even without pipeline
While Eli Lilly and Co.’s stock price is up 16 percent in the past four months, a new analyst covering the company thinks it has more room to grow. And that’s even without launching a new Alzheimer’s drug anytime soon.
IU chemist DiMarchi receives science award from Daniels
Richard DiMarchi helped develop the sepsis-treating drug Xigris for Eli Lilly and Co. He also co-founded Marcadia Biotech, which Roche acquired in 2010 for an initial upfront payment of $287 million.
Lilly notifies Canada about NAFTA complaint on Strattera patent
Eli Lilly and Co. notified Canada it plans to file a trade complaint, claiming court decisions invalidating one of the company’s patents breach international obligations.
Cornerstone content with small medical developments
Local firm has carved out niche building for hospitals, physician groups.
Nico raises $6.5 million more from existing investors
Indianapolis-based Nico Corp. wants to use its new round of capital to develop brain surgery products to address diseases that were often considered inoperable, such as metastatic brain cancer and intracerebral hemorrhages.
Illinois company to hire 50 in Indy for Medicaid drug contract
Catamaran Corp. will add 50 jobs in Indianapolis over the next year to help it provide pharmacy-benefit-management services to the Indiana Medicaid program. The Illinois-based company will open an office downtown Tuesday to kick off its six-year, $60 million contract with the state.